SEC Company Response from HARVARD BIOSCIENCE INC (HBIO) (CIK 0001123494) (HBIO) — May 8, 2018
HARVARD BIOSCIENCE INC (HBIO) (CIK 0001123494)
Date: May 8, 2018 · CIK: 0001123494 · Accession: 0001171843-18-003672
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-224535
Letter
Harvard Bioscience, Inc.
84 October Hill Road
Holliston, Massachusetts 01746
May 8, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Re: Harvard Bioscience, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333-224535
Request for Acceleration
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company respectfully requests acceleration by the Securities and Exchange Commission (the “Commission”) of the effective date of the Registration Statement on Form S-3 (File No. 333-224535) (the “Registration Statement”) of the Company. The Company respectfully requests that the Registration Statement become effective as of 4:30 p.m., Washington, D.C. time, on May 9, 2018, or as soon as practicable thereafter.
The Company respectfully requests that it be notified of such effectiveness by a telephone call to Chad J. Porter of Burns & Levinson LLP at (617) 345-3686 and that such effectiveness also be confirmed in writing.
If you have any further questions or comments, or if you require any additional information, please contact the undersigned by telephone at (508) 893-9999 or our attorney, Chad J. Porter at the number above. Thank you for your assistance.
Very truly yours,
Harvard Bioscience, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Harvard Bioscience, Inc.
84 October Hill Road
Holliston, Massachusetts 01746
May 8, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Re: Harvard Bioscience, Inc. (the “Company”)
Registration Statement on Form S-3
File No. 333-224535
Request for Acceleration
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities
Act of 1933, as amended, the Company respectfully requests acceleration by the Securities and Exchange Commission (the “Commission”)
of the effective date of the Registration Statement on Form S-3 (File No. 333-224535) (the “Registration Statement”)
of the Company. The Company respectfully requests that the Registration Statement become effective as of 4:30 p.m., Washington,
D.C. time, on May 9, 2018, or as soon as practicable thereafter.
The Company respectfully requests that it
be notified of such effectiveness by a telephone call to Chad J. Porter of Burns & Levinson LLP at (617) 345-3686 and that
such effectiveness also be confirmed in writing.
If you have any further questions or comments,
or if you require any additional information, please contact the undersigned by telephone at (508) 893-9999 or our attorney, Chad
J. Porter at the number above. Thank you for your assistance.
Very truly yours,
Harvard Bioscience, Inc.
By: /s/ Robert E. Gagnon
Name: Robert E. Gagnon
Title: Chief Financial Officer
cc: Jeffrey A. Duchemin, Chief Executive Officer, Harvard Bioscience, Inc.
Josef B. Volman, Esq., Burns
& Levinson LLP